Adma Biologics Inc (NASDAQ: ADMA) is 283.85% higher on its value in year-to-date trading and has touched a low of $3.06 and a high of $18.48 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADMA stock was last observed hovering at around $17.46 in the last trading session, with the day’s loss setting it -0.11%.
Currently trading at $17.35, the stock is 13.79% and 30.22% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.33 million and changing -0.63% at the moment leaves the stock 122.11% off its SMA200. ADMA registered 339.24% gain for a year compared to 6-month gain of 214.31%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 40.37% loss in the last 1 month and extending the period to 3 months gives it a 82.44%, and is -3.23% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.91% over the week and 5.28% over the month.
Adma Biologics Inc (ADMA) has around 624 employees, a market worth around $4.04B and $330.24M in sales. Current P/E ratio is 123.40 and Fwd P/E is 26.49. Profit margin for the company is 10.53%. Distance from 52-week low is 466.99% and -6.11% from its 52-week high. The company has generated returns on investments over the last 12 months (10.59%).
The EPS is expected to grow by 471.15% this year.
Adma Biologics Inc (ADMA) Top Institutional Holders
333.0 institutions hold shares in Adma Biologics Inc (ADMA), with institutional investors hold 82.25% of the company’s shares. The shares outstanding are 226.06M, and float is at 225.13M with Short Float at 4.00%. Institutions hold 80.10% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 18.64 million shares valued at $208.45 million. The investor’s holdings represent 8.1462% of the ADMA Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 14.52 million shares valued at $162.3 million to account for 6.3426 of the shares outstanding. The other top investors are INVESCO LTD. which holds 13.17 million shares representing 5.7546% and valued at over $147.25 million, while NUVEEN ASSET MANAGEMENT, LLC holds 3.8996 of the shares totaling 8.93 million with a market value of $99.78 million.
Adma Biologics Inc (ADMA) Insider Activity
The most recent transaction is an insider sale by Grossman Adam S, the company’s President and CEO. SEC filings show that Grossman Adam S sold 389,356 shares of the company’s common stock on Aug 27 ’24 at a price of $17.29 per share for a total of $6.73 million. Following the sale, the insider now owns 2.06 million shares.
Adma Biologics Inc disclosed in a document filed with the SEC on Aug 26 ’24 that Grossman Adam S (President and CEO) sold a total of 236,889 shares of the company’s common stock. The trade occurred on Aug 26 ’24 and was made at $17.69 per share for $4.19 million. Following the transaction, the insider now directly holds 2.06 million shares of the ADMA stock.
Still, SEC filings show that on Aug 23 ’24, KWON YOUNG (Director) disposed off 60,000 shares at an average price of $18.26 for $1.1 million. The insider now directly holds 241,441 shares of Adma Biologics Inc (ADMA).
